Obinutuzumab (anti-CD20)

製品コードA2023 別名: Gazyva, GA101, Gazyvaro, Afutuzumab

製品コード：A2023 純度：99.65%

Obinutuzumab (Gazyva, GA101, Gazyvaro, Afutuzumab) (anti-CD20) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukemia and lymphoma of B-cell origin.

サイズ	価格(税別)	在庫状況
1mg	JPY 44500	国内在庫あり
5mg	JPY 146500	国内在庫あり
1mg*5	JPY 146500	お問い合わせ
1mg*25	JPY 445500	お問い合わせ

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

質量管理及び製品安全説明書

現在のバッチを見る： A202301 純度： 99.65% タンパク質濃度： 5 mg/ml 内毒素： ≤1 EU/mg

99.65

CD markers阻害剤の選択性比較

生物活性

製品説明	Obinutuzumab (Gazyva, GA101, Gazyvaro, Afutuzumab) (anti-CD20) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed for lymphocytic leukemia and lymphoma of B-cell origin.

In Vitro
In Vitro	GA101 is the first Fc-engineered, type II humanized IgG1 antibody against CD20. Relative to rituximab, GA101 has increased direct and immune effector cell-mediated cytotoxicity and exhibits superior activity in cellular assays and whole blood B-cell depletion assays.^[3]
細胞実験	Objective: Annexin V/PI FACS assay Cells: NHL cell lines Concentrations: 10 μg/mL Incubation Time: 36 hr Method: For CD40 stimulation of hCD20 cells from transgenic mice, red blood cells (RBCs) are removed by hypotonic ammonium-chloride-potassium (ACK) lysis, and untouched splenic B cells are purified by anti-CD43–mediated depletion of non-B cells (MACS). B cells are incubated in conditioned complete RPMI 1640 medium containing 10% fetal bovine serum for 2 hours (with or without 10 μg/mL mitogenic stimulation) and either anti-CD40 or anti-IgM Fab2 antibodies. This is followed by 36 hours of anti-CD20 stimulation (GA101 or rituximab 10 μg/mL). As positive controls for the induction of cell death, the following agents are used: 100nM staurosporine for mitochondrial-mediated apoptosis, or 1 μg/mL anti-CD95 Fas for the extrinsic induction of apoptosis. Reference: https://pubmed.ncbi.nlm.nih.gov/20194898/ Obinutuzumab can apply to humanized mice (eg:SCID beige mice), peripheral blood and other related assays (Only for Reference)

In Vivo
In Vivo	In human lymphoma xenograft models, GA101 exhibits superior antitumor activity, resulting in the induction of complete tumor remission and increased overall survival. In nonhuman primates, GA101 demonstrates superior B cell–depleting activity in lymphoid tissue, including in lymph nodes and spleen.^[3]
動物試験	Objective: Tumor control ratio (TCR) and tumor growth inhibition (TGI) Animal Models: 4- to 8-week-old female SCID beige mice Formulation: -- Dosages: 30 mg/kg Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/24304419/ Objective: NHL xenograft studies in SCID beige mice Animal Models: 4 to 5-week-old female SCID beige mice Formulation: -- Dosages: 10 mg/kg, 30 mg/kg Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/20194898/ Obinutuzumab can apply to humanized mice (eg:SCID beige mice), peripheral blood and other related assays (Only for Reference)

参考
[1] Kensei Tobinai, et al. Adv Ther . 2017 Feb;34(2):324-356. [2] Frank Herting, et al. Leuk Lymphoma. 2014 Sep;55(9):2151-5160. [3] Ekkehard Mössner, et al. Blood. 2010 Jun 3;115(22):4393-402.

参考

製品説明

CAS No.	949142-50-1
Formulation	PBS buffer, pH 7.2
Isotype	Human IgG1 isotype control
Source	Humanized (from mouse)
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping	Shipped under low temperature conditions
Sterility	5 mg/ml

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須